PMVP Overview

Clinical Trial Results: Updated data from the Phase 2 PYNNACLE trial presented at the 2025 AACR-NCI-EORTC Conference showed a 34% overall response rate (ORR) across eight tumor types, with a notable 46% ORR in the ovarian cancer cohort.

Rezatapopt Overview: Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate the p53 protein in tumors with the TP53 Y220C mutation, with plans for a New Drug Application submission for platinum-resistant ovarian cancer in Q1 2027.

Safety Profile: The treatment was generally well-tolerated, with most adverse events being Grade 1-2, and a low discontinuation rate due to treatment-related adverse events (3.6%).

Future Directions: PMV Pharma aims to continue generating data to support regulatory strategies and enhance treatment options for patients with advanced solid tumors harboring the TP53 Y220C mutation.

Clinical Trial Results: PMV Pharmaceuticals released interim data from the Phase 2 PYNNACLE trial, showing a 33% overall response rate for rezatapopt in patients with advanced solid tumors harboring the TP53 Y220C mutation, with notable efficacy in ovarian (43% ORR) and endometrial (60% ORR) cancers.

Safety and Regulatory Plans: The treatment was generally well-tolerated, with most adverse events being mild. PMV Pharma plans to enroll additional patients for a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer by early 2027, following FDA feedback.

Positive Interim Data: PMV Pharmaceuticals announced positive interim results from the Phase 2 portion of the PYNNACLE study, showing a 33% overall response rate in patients with advanced solid tumors, particularly those with TP53 Y220C mutations and KRAS wild-type.

Ovarian Cancer Focus: The study reported a 43% response rate in the ovarian cancer cohort, with a median duration of response of 7.6 months, and the company plans to submit a New Drug Application for rezatapopt in platinum resistant/refractory ovarian cancer by Q1 2027.

Insider Trading Activity: Robert Ticktin, General Counsel & COO of $PMVP, sold 23,151 shares of the company, representing about 19% of his holdings, and now owns 98,695 shares. In the past six months, there have been four insider sales with no purchases.

Institutional Investor Movements: In the latest quarter, 10 institutional investors increased their positions in $PMVP stock while 48 reduced theirs, indicating mixed sentiment among institutional stakeholders.